We describe the case of a patient with a diagnosis of rheumatoid
arthritis experiencing a mucocutaneous delayed reaction to golimumab.
Anyway, there is no consensus regarding the best management of delayed
reactions to biologics. Excluding allergic cross-reactivity or
sensitization, we finally tested adalimumab by a graded challenge.